Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2029

Conditions
Lung Cancer
Interventions
DRUG

Sacituzumab Govitecan

"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"

DRUG

Pembrolizumab

"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"

Trial Locations (4)

Unknown

RECRUITING

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

RECRUITING

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong

RECRUITING

Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong

RECRUITING

Department of Oncology, Princess Margaret Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER